EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study

Marije Van Schalkwyk iD, Adrie Bekker, Eric Decloedt, Jiajia Wang, Gerhard B Theron, Mark F Cotton, Ahizechukwu C Eke, Tim R Cressey iD, Deo Wabwire, David E Shapiro, Kira Bacon, Kevin Knowles und 10 weitere

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00052-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Marije Van Schalkwyk und 21 weiteren Autor:innen. Beteiligte Einrichtung: Division of Adult Infectious Diseases, Department of Medicine, Family Center for Research with Ubuntu, Stellenbosch University and Tygerberg Hospital…. Hauptthemen laut MEDLINE: Benzoxazines, Isoniazid, Antitubercular Agents, Rifampin. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NICHD NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The pharmacokinetics (PK) of antituberculosis drugs may be altered by both pregnancy-induced physiological changes and drug interactions in individuals living with HIV who develop tuberculosis. Within the multicenter International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1026s study, we assessed the PK of rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum (PP) in women on efavirenz-based antiretroviral therapy (ART). Results were compared to a previously published non-HIV group and described minimum targets. World Health Organization-recommended daily doses of antituberculosis and ART medications were administered, followed by PK sampling of all antituberculosis drugs over 24 h during the second trimester (2T), third trimester (3T), and 2–8 weeks PP. PK parameters were characterized using noncompartmental analysis, and comparisons were made among stages of pregnancy and between groups using geometric mean ratios with 90% confidence intervals. Twenty-two participants were enrolled, and PK data were available for 12, 20, and 13 participants in 2T, 3T, and PP, respectively. While no significant difference in rifampin exposure between pregnancy and postpartum was detected, the median area-under-the-plasma-concentration-time-curve up to 24 h post-dose (AUC 0–24 ) and C max were below target during each period and were 42% and 35% lower in 3T than the non-HIV group. No significant difference in isoniazid exposure was found between pregnancy and PP or between the groups. Ethambutol and pyrazinamide AUC 0–24 and C max in 2T and 3T were similar between the groups. In both groups, pyrazinamide C max was above target in all periods. The clinical relevance of lower rifampin exposure in pregnant women requiring tuberculosis treatment while on efavirenz should be determined.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BenzoxazinesIsoniazidAntitubercular AgentsRifampinPyrazinamideEthambutolHIV InfectionsTuberculosisAnti-HIV AgentsHumansFemalePregnancyCyclopropanesAdultAlkynesPostpartum PeriodAdolescentYoung Adult

Stichwörter der Autor:innen

antiretroviral therapydrug-susceptible tuberculosisefavirenzethambutolisoniazidpharmacokineticspregnancypyrazinamiderifampin

Substanzen

CyclopropanesBenzoxazinesIsoniazidAntitubercular AgentsRifampinefavirenzPyrazinamideAlkynesEthambutolAnti-HIV Agents

Autor:innen und Institutionen

  • Division of Adult Infectious Diseases, Department of Medicine, Family Center for Research with Ubuntu, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • Department of Pediatrics and Child Health, Family Center for Research with Ubuntu, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • Division of Clinical Pharmacology, Department of Medicine, Stellenbosch University and Tygerberg Hospital, Cape Town, South Africa.
  • Department of Biostatistics, Harvard T.H. Chan School of Public Health, Center for Biostatistics in AIDS Research, Boston, Massachusetts, USA.
  • Department of Obstetrics and Gynecology, Stellenbosch University, Cape Town, South Africa.
  • Division of Maternal Fetal Medicine and Clinical Pharmacology, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Marije Van Schalkwyk, Tim R Cressey, Lubbe Wiesner

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • NICHD NIH HHS
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Van Schalkwyk, M., Bekker, A., Decloedt, E., Wang, J., Theron, G. B., Cotton, M. F., Eke, A. C., Cressey, T. R., Wabwire, D., Shapiro, D. E., Bacon, K., Knowles, K., George, K., Browning, R., Chakhtoura, N., Rungruengthanakit, K., Wiesner, L., Capparelli, E. V., Stek, A. M., …, & IMPAACT P1026s Protocol Team (2025). Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00052-25

Vancouver

Van Schalkwyk M, Bekker A, Decloedt E, Wang J, Theron GB, Cotton MF, et al. Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00052-25

BibTeX
@article{VanSchalkwyk2025,
  author = {Van Schalkwyk, Marije and Bekker, Adrie and Decloedt, Eric and Wang, Jiajia and Theron, Gerhard B and Cotton, Mark F and Eke, Ahizechukwu C and Cressey, Tim R and Wabwire, Deo and Shapiro, David E and Bacon, Kira and Knowles, Kevin and George, Kathleen and Browning, Renee and Chakhtoura, Nahida and Rungruengthanakit, Kittipong and Wiesner, Lubbe and Capparelli, Edmund V and Stek, Alice M and Mirochnik, Mark and Best, Brookie M and IMPAACT P1026s Protocol Team, IMPAACT P1026s Protocol Team},
  title = {Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00052-25}
}
Kostenlos starten →